Cidara Therapeutics And Mundipharma Announce Positive Topline Results From The Global Phase 3 Pivotal ReSTORE Trial Of Rezafungin For The Treatment Of Candidemia And Invasive Candidiasis; Trial Met FDA And EMA-Pre-Specified Primary Endpoints